Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

UNH surpasses centennial fundraising goal

The University of New Haven has announced that its first-ever comprehensive fundraising campaign has surpassed its original goal of $100 million. The ambitious nine-figure target,...

| By Bill Kelly

SpringWorks completes $125 million Series B

SpringWorks Therapeutics reports the closing of a $125 million Series B preferred stock financing led by Perceptive Advisors. Proceeds from the financing will be used to...

| By Bill Kelly

Arvinas makes two new internal appointments

Arvinas reports that two members of the senior leadership team were appointed to expanded roles at the company. Andy Crew, Ph.D., has been appointed Chief Technology...

| By Bill Kelly

BioCT welcomes new member Greenfield BioVentures

Greenfield BioVentures is an investment company focused on early-stage science in the biopharmaceuticals space. Its preferred investments are typically in pre-clinical stages of experimentation and in...

| By Bill Kelly

GestVision reports on urine test for preeclampsia

GestVision reports researchers have demonstrated that CRD (Congo Red Dot) urine diagnostic test results strongly correlate with a diagnosis of preeclampsia. “This is an important...

| By Bill Kelly

Biohaven acquires Priority Review Voucher

Biohaven Pharmaceutical Holding Company has purchased an FDA Priority Review Voucher to use with the NDA submission of rimegepant Zydis® ODT in the second quarter of 2019 …...

| By Kelley Gipson

Cybrexa unveils rucaparib as PARP inhibitor

Cybrexa Therapeutics reports that the FDA- and EMA-approved poly ADP-ribose polymerase (PARP) inhibitor rucaparib (marketed as Rubraca®) is conjugated in lead candidate CBX-11 (alphalex™-rucaparib). The...